NASDAQ: QURE

uniQure N.V.

Healthcare | Biotechnology

No licensed closing price on file for QURE. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.49

uniQure N.V. (NASDAQ: QURE) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 15:26 UTC.

What uniQure N.V. does

The company is developing gene therapies designed to provide single treatments with potentially curative effects for patients with rare and devastating diseases. Its pipeline includes clinical candidates for Huntington's disease, refractory mesial temporal lobe epilepsy, Fabry disease, and a form of amyotrophic lateral sclerosis caused by SOD1 mutations. The company's most advanced program, AMT-130 for Huntington's disease, showed positive results in a Phase I/II study with statistically significant slowing of disease progression measured by multiple clinical scales.

Summarized from uniQure N.V.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	8-K 2026-06-24
EPS (TTM)	$-3.49
Debt/equity	0.33

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-07-07

Most recent filed transactions — July 2026:

2026-07-07CEO, Managing DirectorStock Option (Right to Buy)Option exercise-21,082—
2026-07-07CEO, Managing DirectorSale-7,600$348.8K
2026-07-07CEO, Managing DirectorSale-9,200$408.8K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Avoro Capital Advisors LLC6,727,777$309.88M+12.9%
JPMORGAN CHASE & CO4,867,755$230.81M+71.5%
RTW INVESTMENTS, LP3,941,572$181.55M+52.4%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2021-06-21Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2019-04-29AuditorChanges in registrant's certifying accountantPwCAuthoritativeSEC 8-K →

Company news

View all →

uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing Transcript
Seeking Alpha Feed2026-09-29
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does uniQure N.V. do?

The company is developing gene therapies designed to provide single treatments with potentially curative effects for patients with rare and devastating diseases.

When did QURE last file with the SEC?

uniQure N.V.'s most recent SEC filing on record is a 8-K filed 2026-06-24. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 15:26 UTC. This page is also available as JSON at /api/data?ticker=QURE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for QURE and 5,000+ tickers.

Create a free account — keep QURE

For your agent

GET /api/data?ticker=QURE

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt